Newsquawk Logo

Regeneron's (REGN) Dupixent (dupilumab) approved in the US as the first and only medicine for Allergic Fungal Rhinosinusitis

Regeneron's approval of Dupixent as the first and only treatment for Allergic Fungal Rhinosinusitis is a significant milestone, enhancing its product portfolio and potentially opening up a new revenue stream.

Newsquawk StaffPublished On the live feed at — 11 more headlines followed before this page went public
Newsquawk headlinesUTC

Honda (9267 JT) has suspended its operations at its Guadalajara Mexican plant over cartel rampage, FT reports

Anthropic unveiled 10 new ways for business customers to plug in its tech to key areas of work; could help with Investment Banking tasks like reviewing deals, Wealth-Management tasks such as portfolio analysis and HR related tasks

Regeneron's (REGN) Dupixent (dupilumab) approved in the US as the first and only medicine for Allergic Fungal Rhinosinusitis

India Trade Minister says it will resume trade talks with the US once there is more clarity on tariffs

Home Depot (HD) CFO announce that they anticipate pressures from economic uncertainty to continue to persist in fiscal 2026

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.
Context

This development may position Regeneron favorably against competitors in the biotechnology space, particularly if it successfully captures market share in this niche area. Investors will want to consider the regulatory landscape and market response, as well as any implications for future M&A activity in the sector.

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.